These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7779283)

  • 1. [Humoral immune response to the proteins of an antimeningococcal BC vaccine in a trial carried out in Antioquia, Colombia].
    Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Blanco González R; Martínez Ruiz O; Martínez Fernández OM; Aguirre Muñoz CA
    Bol Oficina Sanit Panam; 1995 Apr; 118(4):285-94. PubMed ID: 7779283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Humoral immune response to the capsular polysaccharide of Neisseria meningitidis serogroup C in an antimeningococcal BC vaccination trial in Antioquia, Colombia].
    Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Martínez Ruiz O; Nerey MC; Camarasa MA; Bacallao Gallestey J
    Bol Oficina Sanit Panam; 1995 Apr; 118(4):295-301. PubMed ID: 7779284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenecity induced by the VA-MENGOC-BC antimeningococcal vaccine against the ATCC C11. N. meningitidis strain in adolescents 12 years after being vaccinated].
    Camaraza MA; Ochoa R; Arnet AG; Sotolongo F; Martínez I; Cuevas I; Hernández D
    Rev Cubana Med Trop; 2004; 56(1):26-30. PubMed ID: 15849905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Levels of bactericidal antibodies against meningococcus C after vaccination in 2- to 6-year-old children in Andalusia].
    Delgado Torralbo E; Vazquez Moreno JA; García León J; González Enríquez J; Martínez Navarro F; Berrón Morato S; Mayoral Cortés JM; Rubin Gómez MA; Méndez Martínez C; Cortés Majó M; Chaves Caballero M; Bernal González ML
    Rev Esp Salud Publica; 2000; 74(4):433-44. PubMed ID: 11031854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness and duration of the immunity of the vaccine against serogroup A+C meningococcus].
    García Comas L; Ramírez Fernández R; Castañeda López R; Sanz Moreno JC; Vázquez Moreno J; Lasheras Carbajo MD; Barranco Ordoñez D; Ruiz Contreras J; Jover Ibarra J
    Rev Esp Salud Publica; 2000; 74(4):425-31. PubMed ID: 11031853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of a serologic study after vaccination against serogroup C Neisseria meningitidis in children].
    Espín Ríos MI
    Rev Esp Salud Publica; 2000; 74(4):445-8. PubMed ID: 11031855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
    Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
    Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [VA-MENGOC-BC vaccine: its impact on meningococcal disease in children 1-4 years old].
    Pérez Rodríguez A; Meneses FO
    Rev Cubana Med Trop; 1999; 51(3):189-93. PubMed ID: 10887587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
    Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
    JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hyperferremic mouse model for the evaluation of the effectiveness of VA-MENGOC-BC against Neisseria meningitidis B clinical isolates.
    Sifontes S; Infante JF; Pérez P; Caro E; Sierra G; Campa C
    Arch Med Res; 1997; 28(1):41-5. PubMed ID: 9078586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37.
    Krizova P; Musilek M
    Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.
    Frøholm LO; Berdal BP; Bøvre K; Gaustad P; Harboe A; Holten E; Høiby EA; Lystad A; Omland T; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):133-8. PubMed ID: 6427703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.
    de Kleijn ED; de Groot R; Lafeber AB; Labadie J; van Limpt CJ; Visser J; Berbers GA; van Alphen L; Rümke HC
    J Infect Dis; 2001 Jul; 184(1):98-102. PubMed ID: 11398116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
    Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
    Tappero JW; Lagos R; Ballesteros AM; Plikaytis B; Williams D; Dykes J; Gheesling LL; Carlone GM; Høiby EA; Holst J; Nøkleby H; Rosenqvist E; Sierra G; Campa C; Sotolongo F; Vega J; Garcia J; Herrera P; Poolman JT; Perkins BA
    JAMA; 1999 Apr; 281(16):1520-7. PubMed ID: 10227322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.